drugset / Trial / NCT06197295

Efficacy of Combined Pharmacotherapy Versus Solifenacin With Vaginal Estrogen Cream for Women With Detrusor Overactivity

NCT06197295

Phase 4 Recruiting 200 enrolled Mackay Memorial Hospital
Non-randomizedParallel-groupDouble-blindTreatment

Summary

To investigates the effects of combined pharmacotherapy with solifenacin and mirabegron versus solifenacin with vaginal estrogen cream in women with detrusor overactivity.

Timeline

Start
2022-06-16
Primary completion
2026-06-30
Completion
2026-12-31

Drugs

EvaluationDrugModalityDoseRoute
Comparator Mirabegron Other / unclassified 25 mg
Subject conjugated estrogens Other / unclassified 0.625 mg Other
Background Solifenacin Small molecule 5 mg

Indications